EQS-News: SCHOTT Pharma delivers on full-year revenue and profitability targets

SCHOTT Pharma delivers on full-year revenue and profitability targets

• Revenue of EUR 986.2m reflects a 5.8% growth at constant currencies
• EBITDA margin at constant currencies increased to 28.4% (prior year: 26.9%)
• Successful expansion of high-value solutions (HVS) – revenue share increased to 57% (prior year: 55%)
• Guidance for FY 2026: 2-5% revenue growth at constant currencies and EBITDA margin of around 27%

SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, has successfully concluded its fiscal year 2025¹.Revenue rose to EUR 986.2m, representing an increase of 5.8% at constant currencies (reported +3.0%). Full-year EBITDA grew even stronger and amounted to EUR 280.3m, up 11.5% at constant currencies (reported +8.8%). The corresponding EBITDA margin was 28.4% (reported 28.4%).

“Amid the challenging macroeconomic environment, SCHOTT Pharma once again delivered excellent results, and we met our targets for both revenue and profitability. While our core solutions remain a very solid and profitable business, we have effectively continued to focus on increasing the revenue share of our high-value solutions through product innovation, capacity expansions, and strong partnerships,” said SCHOTT Pharma’s CEO Andreas Reisse. “As we expect the market to remain difficult, we target a revenue growth of 2-5% for fiscal year 2026 and an EBITDA margin of around 27%. This represents a bridge year, as we anticipate market dynamics to pick up again going forward. We update our mid-term guidance and now project a revenue CAGR of 6-8% and an incremental increase of our EBITDA margin over the coming years.”

Reinhard Mayer, CFO of SCHOTT Pharma, adds: “The disciplined execution of our strategy in 2025 has further strengthened SCHOTT Pharma’s financial foundation and bolstered our resilience against the backdrop of geopolitical uncertainties. Over the last six years, we have invested around EUR 800m in our global manufacturing network, particularly for high-value solutions. At the same time, we have further improved our efficiency through automation and digitization, which is also reflected in the positive development of our EBITDA margin. Looking ahead, we remain committed to investing in innovation, capacity and operational excellence to drive sustainable, profitable growth alongside our mid-term expectations.”

Profitable growth driven by high-value solutions

SCHOTT Pharma’s positive development was driven by the Drug Containment Solutions segment (DCS), where revenue increased 11.9% at constant currencies (reported +5.6%) to EUR 548.0m. High-value solution products like sterile ready-to-use cartridges and vials as well as specialty vials for innovative biologic drugs performed particularly well. As a consequence, the segment’s HVS revenue share grew by 6pp to 23%. EBITDA in the DCS segment rose to EUR 127.5m, marking a significant surge of 34.9% at constant currencies (reported +26.0%) due to a favorable product mix and efficiency gains. The corresponding margin went up by 4.0pp to 23.5% (reported 23.3%).

Revenue in the Drug Delivery Systems (DDS) segment were at EUR 438.8m, representing a slight decline of 1.3% at constant currencies (reported: 0.0%). The lower demand for polymer syringes was offset by the sustained high demand for prefillable glass syringes. EBITDA decreased by 9.9% at constant currencies (reported -8.2%) to EUR 152.8m, mainly due to lower utilization as well as ramp-up costs for the new prefillable glass syringe manufacturing facility in Hungary. The segment´s EBITDA margin was at 34.6% at constant currencies (reported 34.8%), down 3.3pp on the previous year’s figure.

Solid cash generation and high growth investments

SCHOTT Pharma's operating cash flow came in at EUR 179.9m in the reporting year, after EUR 224.8m in 2024. This was mainly due to a higher working capital need and timing of tax payments, which more than offset the EBITDA improvement. At EUR 144.8m, CAPEX was on par with the previous year's level, as the company continued to invest in capacity expansion, particularly for high-value solutions.

Earnings per share for the reporting year were EUR 0.97 (prior year: EUR 0.99). The Management Board and Supervisory Board will propose a dividend of EUR 0.18 per share for FY 2025 at the Annual General Meeting on February 3, 2026. That would result in a payout ratio of 18% of the profit for the period.

Addressing market needs, preparing for future growth

In fiscal year 2025, SCHOTT Pharma launched several product innovations addressing major market trends, such as the increasing demand for solutions that enable the safe and easy self-administration of injectable drugs at home; the growing and increasingly diverse range of sensitive biologics; as well as the need for a more sustainable manufacturing and reliable supply of drugs and vaccines. The portfolio additions include sterile large-volume syringes and cartridges made of glass and polymer, which further strengthen the company’s product range of high-value solutions.

At the same time, SCHOTT Pharma continued to execute its multi-year expansion plan and achieved important milestones. The company opened a new production site in Serbia and celebrated the groundbreaking for a new facility for sterile ready-to-use cartridges in Hungary.

Outlook

SCHOTT Pharma expects revenue growth at constant currencies of 2-5% for fiscal year 2026 and the EBITDA margin to be around 27%. The sales growth will be entirely driven by the DCS segment. At the same time, the DDS segment will be impacted by the unexpected revised market outlook of a key customer resulting in lower glass syringes demand. Product mix effects and a temporary underutilization of capacities in DDS, as well as ramp-up costs for new factories in Serbia and Hungary is impacting the EBITDA margin in 2026.

Based on this, SCHOTT Pharma updates its mid-term outlook for 2027 to 2029 to a revenue CAGR of 6-8% and expects the EBITDA margin to improve over the coming years towards 30%.

New CEO appointed

On November 5, 2025, SCHOTT Pharma announced that Christian Mias will succeed Andreas Reisse as CEO, effective May 1, 2026. Mias has 20 years of management experience, thereof more than 18 years within the SCHOTT group. There, he has held leadership positions across various business units and continents, in which he drove profitable growth by optimizing processes, improving productivity, and increasing earnings quality. His career also included roles at SCHOTT Tubing, which manufactures glass tubing for the pharmaceutical sector, including for SCHOTT Pharma, where he gained significant experience in the pharmaceutical industry.

For additional news about SCHOTT Pharma, please visit our media center.

Key figures FY 2025

Key figures Q4 2025

Differences in the total numbers in the tables may be due to rounding, and differences in group revenue may result from consolidation and reconciliation effects. / nm = not meaningful

¹The fiscal year runs from October to September. Q4 2025 therefore relates to the period from July 2025 to September 2025.
²cc = at constant currencies

Webcast

CEO Andreas Reisse and CFO Reinhard Mayer will speak at an analyst and investor conference call at 11:00 a.m. CET on 11 December 2025 to discuss the Q4 and FY 2025 results. The audio webcast can be followed via the following link. The accompanying presentation is available on the IR website: www.schott-pharma.com/investor-relations

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs containment solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 30,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,800 people from over 65 nations works at SCHOTT Pharma to contribute to global health. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 986 million in the fiscal year 2025. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Further information at www.schott-pharma.com

Press contact

Lea Kaiser

PR & Communications Manager

Tel.: +49 (0) 151 68917195

E-Mail : lea.kaiser@schott.com

Katrin Schreyer

Global Communications Manager

Tel.: +49 (0) 171 116 7544

E-Mail : katrin.schreyer@schott.com

Investor Relations contact

Tobias Erfurth

Head of Investor Relations

Jasko Terzic

Senior Manager Investor Relations

E-Mail: ir.pharma@schott.com